---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-080622"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-07-23T11:30:22+00:00"
generated_at: "2026-07-23T11:35:16.116366+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Incannex commences participant screening in Phase 2 DReAMzz study of IHL-42X for obstructive sleep apnea

## Summary
- First clinical sites approved and actively screening participants for DReAMzz Phase 2 dose confirmation study of IHL-42X.
- IHL-42X has FDA Fast Track designation, supporting potentially expedited regulatory pathway.
- Prior Phase 2 data showed up to 83% reduction in AHI and significant improvements in patient-reported outcomes.
- No FDA-approved oral pharmaceutical therapies currently available for OSA, affecting ~1 billion people globally.
- Study designed to optimize dosing profile and strengthen regulatory package ahead of planned Phase III development.

## SEC filing metadata
- accession: 0001213900-26-080622
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-07-23T11:30:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/0001213900-26-080622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea0298674-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-080622
- JSON: https://secwatch.observer/filing/0001213900-26-080622.json
- Plain text: https://secwatch.observer/filing/0001213900-26-080622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.